[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-435960-105":59,"doc-detail-435960-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","erratum-guidelines-for-parkinsons-disease-management-part-ii","Erratum - Guidelines for Parkinson's disease management part II","","This document serves as a formal erratum for the article titled \"Guidelines for Parkinson’s disease management part II: consensus from the movement disorders scientific department of the Brazilian Academy of Neurology – non-motor symptoms,\" originally published in Arq. Neuro-Psiquiatr. 2025;83(1):s00451802962 (DOI: 10.1055/s-0045-1802962). The correction clarifies the pharmacological treatment recommendations for patients with Parkinson's disease with mild cognitive impairment (PD-MCI) or prodromal dementia with Lewy bodies (DLB). Specifically, it updates the consensus to state that Donepezil and rivastigmine are not recommended for the treatment of these patient groups, correcting a previous oversight in the published guideline. This publication ensures the accuracy of clinical recommendations for neurologists and healthcare professionals managing Parkinson's disease-related non-motor symptoms.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/erratum-guidelines-for-parkinsons-disease-management-part-ii/435960/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/erratum-guidelines-for-parkinsons-disease-management-part-ii/435960.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the purpose of this document?","Question",{"text":113,"@type":114},"This document is an erratum to correct a specific pharmacological recommendation regarding the treatment of Parkinson's disease patients with mild cognitive impairment or prodromal DLB.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What specific change was made to the guideline?",{"text":118,"@type":114},"The correction clarifies that Donepezil and rivastigmine are not recommended for treating patients with PD-MCI or prodromal DLB, whereas the previous text incorrectly stated they were recommended.",{"name":120,"@type":111,"acceptedAnswer":121},"Which original article is being corrected?",{"text":122,"@type":114},"The article being corrected is \"Guidelines for Parkinson’s disease management part II: consensus from the movement disorders scientific department of the Brazilian Academy of Neurology – non-motor symptoms,\" published in Arq. Neuro-Psiquiatr. 2025;83(1):s00451802962.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},435960,1790764356,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":81,"preview_page_count":4},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article published online: 2025-10-31  \nErratum 1  \nErratum  \nArq. Neuro-Psiquiatr. 2025;83(9):s00451811960 .  \nERRATUM In the article “Guidelines for Parkinson’s disease management part II: consensus from  \nthe movement disorders scientific department of the Brazilian Academy of Neurology – non-motor symptoms”, published in Arq. Neuro-Psiquiatr. 2025;83(1):s00451802962, under DOI number 10.1055/s-0045-1802962,  \nWhere it reads:  \nGENERAL RECOMMENDATIONS FOR THE PHARMACOLOGICAL TREATMENT OF PDD Donepezil and rivastigmine are recommended to treat patients with PD-MCI or prodromal DLB.  \nShould be:  \nGENERAL RECOMMENDATIONS FOR THE PHARMACOLOGICAL TREATMENT OF PDD Donepezil and rivastigmine are not recommended for the treatment of patients with PD-MCI or prodromal DLB.  \nDOI [https://doi.org/](https://doi.org/)[ ](https://doi.org/)10.1055/s-0045-1811960 . ISSN 0004-282X.  \n© 2025 . The Author(s) .  \nThis is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/))  \nThieme Revinter Publicações Ltda. , Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil","cbCaisHxy9cqeSi1","https://ap.wps.com/l/cbCaisHxy9cqeSi1","pdf",105717,"English","# Erratum Details\n## Pharmacological Treatment Correction","[{\"question\":\"What is the purpose of this document?\",\"answer\":\"This document is an erratum to correct a specific pharmacological recommendation regarding the treatment of Parkinson's disease patients with mild cognitive impairment or prodromal DLB.\"},{\"question\":\"What specific change was made to the guideline?\",\"answer\":\"The correction clarifies that Donepezil and rivastigmine are not recommended for treating patients with PD-MCI or prodromal DLB, whereas the previous text incorrectly stated they were recommended.\"},{\"question\":\"Which original article is being corrected?\",\"answer\":\"The article being corrected is \\\"Guidelines for Parkinson’s disease management part II: consensus from the movement disorders scientific department of the Brazilian Academy of Neurology – non-motor symptoms,\\\" published in Arq. Neuro-Psiquiatr. 2025;83(1):s00451802962.\"}]","Erratum - Guidelines for Parkinson's disease management part II | PDF",1790676101]